Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat and Bortezomib in Pancreatic Cancer
NCT01056601Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2010
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in pancreatic cancer (PC), sponsored by Masonic Cancer Center. Started Sep 2010; status: terminated.
02
Drugs
panobinostat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01056601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01056601.